Discover why Eli Lilly and Company is set for a strong 2024 with a robust pipeline, solid financials, and strategic growth ...

Hims & Hers is shifting towards personalized medicine with AI-backed solutions. Find out why HIMS stock is buyable despite ...

The versions affected are called compounded medications, which have the same active ingredients as the name brands. The ...

While the number of prescription fills for GLP-1 receptor agonists has continued to increase, health Insurance coverage for ...

The FDA ordered compounding pharmacies to stop making copycat versions of weight loss drugs like Ozempic and Zepbound now ...

Tirzepatide is available through both the type 2 diabetes medication Mounjaro and weight-loss medication Zepbound. A new study funded by Eli Lilly reports that people without diabetes can lose up ...

Even a little weight loss can work wonders for your health. A study found that people at high risk for developing type 2 diabetes who lost 5-7% of their weight had a 58% lower risk of developing it.

Zepbound is the most effective FDA-approved GLP-1 drug for weight loss. Between Novo and Lilly, the GLP-1 industry has become an oligopoly with even less threat from compounders like Hims & Hers ...

Lilly offers a similar deal for Zepbound. As insurance coverage expands, Hims’ competitive edge is disappearing. Can Hims Survive Without GLP-1s? Outside of weight loss, Hims’ core business is ...

More consistent accumulation demonstrated in bloodstream over a one-week duration with once-daily DehydraTECH-tirzepatide oral capsules as compared to once-weekly injection of Zepbound®As previously a ...

When it comes to clinical weight-loss treatments, GLP-1 therapies have taken the medical sector by storm. What started as off ...